The upper bound of the 2019-guidance range for non-GAAP EPS was lowered slightly; the new non-GAAP EPS range is $1.04-1.08 (vs the prior range of $1.04-1.10).
3Q19 results and forward guidance do not include Bayer’s animal health business, which ELAN is in the process of acquiring (#msg-150629685).
The stock is -4% in PM trading.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.